Forest Investor Says $25B Actavis Offer Is Insufficient

Law360, New York (February 21, 2014, 8:12 PM EST) -- An investor in Carl Icahn-backed Forest Laboratories sued Thursday to block generic drugmaker Actavis PLC’s $25 billion takeover of the company, saying the price is too low and calling the deal “hastily consummated.”

Earlier this week, the boards of directors at both companies announced the cash-and-stock takeover deal. Under the deal’s terms, stockholders in New York-based Forest will receive a payout valued at $89.48 per share at the time of announcement, including $26.04 in cash and the balance in Actavis shares.

The price is a 25...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.